FAQ: Quantum BioPharma Ltd. Annual General and Special Meeting Results and Company Overview
Summary
Quantum BioPharma Ltd. announced the results of its annual general and special meeting held on September 26, 2025, with shareholders representing 100% of Class A votes and 46.352% of Class B votes present. The company is focused on developing treatments for neurodegenerative and metabolic disorders while maintaining strategic investments and partnerships.
What was the main announcement from Quantum BioPharma?
Quantum BioPharma announced the results of its annual general and special meeting of shareholders held on September 26, 2025, in Toronto, detailing shareholder participation and voting representation across different share classes.
When and where was the shareholder meeting held?
The annual general and special meeting was held on September 26, 2025, in Toronto, with shareholders participating both in person and by proxy.
What was the shareholder participation rate at the meeting?
Shareholders representing 12 Class A multiple voting shares (each entitled to 276,660 votes) and 1,769,228 Class B subordinate voting shares were present, accounting for 100% of Class A votes and 46.352% of Class B votes.
What is Quantum BioPharma’s primary business focus?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different development stages.
What is Lucid-MS and what does it treat?
Lucid-MS is Quantum BioPharma’s lead compound developed through its subsidiary Lucid Psycheceuticals Inc., a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma spun out its OTC version of unbuzzd(TM) to Unbuzzd Wellness Inc. and retains 20.11% ownership (as of March 31, 2025), plus receives 7% royalty payments on sales until reaching $250 million, then 3% in perpetuity, while keeping 100% rights for pharmaceutical and medical uses.
What strategic investments does Quantum BioPharma maintain?
Through its wholly owned subsidiary FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
Where can investors find the latest news and updates about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/ and the full press release can be viewed at https://ibn.fm/D5GzF
What voting rights do different share classes have?
Class A multiple voting shares entitle holders to 276,660 votes per share, while Class B shares are subordinate voting shares, with the meeting showing 100% Class A vote representation and 46.352% Class B vote representation.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 238017